Jason N. Butler
Stock Analyst at Citizens
(3.83)
# 3,327
Out of 5,182 analysts
20
Total ratings
65%
Success rate
7.94%
Average return
Main Sectors:
Stocks Rated by Jason N. Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NERV Minerva Neurosciences | Initiates: Market Outperform | $14 | $6.43 | +117.73% | 1 | Apr 15, 2026 | |
| PGEN Precigen | Maintains: Market Outperform | $8 → $9 | $3.96 | +127.27% | 2 | Mar 26, 2026 | |
| NSRX Nasus Pharma | Maintains: Market Outperform | $19 → $18 | $3.18 | +466.04% | 1 | Mar 26, 2026 | |
| ESPR Esperion Therapeutics | Maintains: Market Outperform | $4 → $5 | $1.91 | +161.78% | 1 | Mar 13, 2026 | |
| GHRS GH Research | Maintains: Market Outperform | $39 → $42 | $19.60 | +114.34% | 1 | Mar 6, 2026 | |
| ARGX argenx SE | Maintains: Market Outperform | $925 → $944 | $783.74 | +20.45% | 1 | Feb 27, 2026 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $8 → $10 | $4.04 | +147.52% | 1 | Feb 26, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Market Outperform | $34 → $35 | $22.30 | +56.95% | 3 | Feb 26, 2026 | |
| ACHV Achieve Life Sciences | Initiates: Market Outperform | $19 | $3.96 | +379.80% | 1 | Nov 25, 2025 | |
| RAPP Rapport Therapeutics | Maintains: Market Outperform | $77 → $80 | $35.40 | +125.99% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $22 | $21.43 | +2.66% | 1 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $9 → $17 | $3.31 | +413.60% | 1 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $95 → $114 | $111.90 | +1.88% | 1 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $22 | $7.82 | +181.33% | 1 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $78 | $61.60 | +26.62% | 1 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $19 → $18 | $9.81 | +83.49% | 1 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $91 → $78 | $64.49 | +20.95% | 1 | Aug 6, 2025 |
Minerva Neurosciences
Apr 15, 2026
Initiates: Market Outperform
Price Target: $14
Current: $6.43
Upside: +117.73%
Precigen
Mar 26, 2026
Maintains: Market Outperform
Price Target: $8 → $9
Current: $3.96
Upside: +127.27%
Nasus Pharma
Mar 26, 2026
Maintains: Market Outperform
Price Target: $19 → $18
Current: $3.18
Upside: +466.04%
Esperion Therapeutics
Mar 13, 2026
Maintains: Market Outperform
Price Target: $4 → $5
Current: $1.91
Upside: +161.78%
GH Research
Mar 6, 2026
Maintains: Market Outperform
Price Target: $39 → $42
Current: $19.60
Upside: +114.34%
argenx SE
Feb 27, 2026
Maintains: Market Outperform
Price Target: $925 → $944
Current: $783.74
Upside: +20.45%
Ironwood Pharmaceuticals
Feb 26, 2026
Maintains: Market Outperform
Price Target: $8 → $10
Current: $4.04
Upside: +147.52%
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Market Outperform
Price Target: $34 → $35
Current: $22.30
Upside: +56.95%
Achieve Life Sciences
Nov 25, 2025
Initiates: Market Outperform
Price Target: $19
Current: $3.96
Upside: +379.80%
Rapport Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $77 → $80
Current: $35.40
Upside: +125.99%
Oct 29, 2025
Maintains: Market Outperform
Price Target: $18 → $22
Current: $21.43
Upside: +2.66%
Oct 29, 2025
Maintains: Market Outperform
Price Target: $9 → $17
Current: $3.31
Upside: +413.60%
Sep 25, 2025
Maintains: Market Outperform
Price Target: $95 → $114
Current: $111.90
Upside: +1.88%
Sep 9, 2025
Reiterates: Market Outperform
Price Target: $22
Current: $7.82
Upside: +181.33%
Sep 2, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $61.60
Upside: +26.62%
Aug 13, 2025
Maintains: Market Outperform
Price Target: $19 → $18
Current: $9.81
Upside: +83.49%
Aug 6, 2025
Maintains: Market Outperform
Price Target: $91 → $78
Current: $64.49
Upside: +20.95%